For example, MRG003, an anti-EGFR antibody–drug conjugate, is currently being evaluated in an ongoing Phase III clinical trial (NCT05751512) to assess its efficacy and safety compared to cetuximab or methotrexate in patients with recurrent/metastatic (R/M) HNSCC who have progressed on prior treatments [59]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.